In-Depth Analysis of the Impact of RxSight (RXST)'s Better-Than-Expected Q4 Results

Based on the comprehensively collected data above, I now present to you an in-depth analysis report on RxSight’s better-than-expected Q4 results.

---

RxSight released its preliminary fourth-quarter 2024 results on January 11, 2026, reporting revenue of

, which significantly exceeded its previously provided full-year 2025 guidance range of $125-$130 million. [0][1]

• LAL (Light Adjustable Lens) Sales
  : 28,611 units sold in Q4, up 10% quarter-over-quarter, indicating a steady recovery in procedure volume
• LDD (Light Delivery Device) Sales
  : 25 units sold in Q4, with a total of
  1,134 units installed
  by year-end, up 25% year-over-year
• Full-Year LAL Sales
  : 109,615 units, up 12% year-over-year
• Gross Margin
  : Rose to 80%, an improvement of 844 basis points year-over-year
• Cash Reserves
  : Approximately $228 million, with a solid financial position [0]

Despite the better-than-expected Q4 revenue, the company’s full-year revenue of approximately

only slightly exceeded the upper end of the guidance range, which reflects:

• Sharp Drop in LDD Sales
  : Only 25 units sold in Q4, a 68% year-over-year decline
• Underperformance in the First Three Quarters
  : Revenue of $101.87 million in the first three quarters, with full-year growth driven mainly by the single quarter of Q4
• Product Structure Optimization
  : The significant improvement in gross margin indicates an increased proportion of LAL (high-margin products)

---

: $8.84 (as of January 9, 2026)

Time Period	Price Change	Assessment
1-Day	-7.63%	Sharp Decline
5-Day	-15.33%	Continuous Pullback
1-Month	-32.47%	Significant Drop
3-Month	+17.71%	Recent Rebound
YTD	-14.84%	Year-to-Date Decline
1-Year	-71.22%	Severe Oversold
52-Week High	$55.57	Down 84.1% from High
52-Week Low	$6.32	Currently Near Lows

• RSI (14)
  : 15.37 (Extremely oversold territory; typically, a reading <30 signals oversold conditions)
• 50-Day Moving Average
  : $10.68 (Stock price is 16.8% below the moving average)
• 200-Day Moving Average
  : $11.49 (Stock price is 23.1% below the moving average)
• Beta Coefficient
  : 1.14 (Slightly higher volatility than the market)
• Trading Range
  : $8.52 (Support) / $11.22 (Resistance) [0]

: The stock is in an extremely oversold state, with potential for a technical rebound, but the medium-term trend remains weak.

Valuation Metric	Value	Industry Comparison
Market Capitalization	$363 million	Small-Cap Stock
P/S (TTM)	2.31x	Below Historical Average
P/B	1.30x	Near Book Value
P/E	-11.17x	Not Yet Profitable
EV/OCF	-19.91x	Negative Free Cash Flow

• Target Price
  : $10.00 (13.1% upside from current price)
• Rating Distribution
  : 25% Buy | 58.3% Hold | 16.7% Sell
• Overall Rating
  : Hold [0]

---

Metric	Original Guidance	Actual Results	Variance
2025 Revenue	$125-130M	~$134.5M	+3.5-7.6%
Gross Margin	72-74%	80%	+6-8pct

1. Expanded LDD Installation Base
   : 1,134 units in operation will provide a stable foundation for future revenue
2. Increased Market Share
   : Approximately 10% share of the premium IOL market, with 25% of U.S. cataract surgeons already adopting the product
3. Improving Gross Margin Trend
   : Gross margin growth driven by product mix optimization, which is sustainable
4. Growing Procedure Volume
   : 12% year-over-year growth in LAL procedures, with robust demand

1. CFO Transition Risk
   : The CFO’s departure in December 2025 raised concerns about management stability, which BTIG analysts highlighted [2]
2. Volatile LDD Sales
   : Device sales are cyclical, making sustained high growth difficult
3. High Operating Expenses
   : Expected operating expenses of $145-$155 million, putting pressure on profitability
4. Industry Competition
   : Giants like Johnson & Johnson and Abbott continue to invest in the intraocular lens space

Scenario	2026 Revenue Forecast	Year-over-Year Growth	Key Assumptions
Optimistic	$155-165M	+15-23%	Recovery in LDD sales, accelerated LAL penetration
Neutral	$140-150M	+4-11%	Maintain current growth momentum
Conservative	$130-140M	-3-4%	Slower growth, intensified competition

---

1. Technological Exclusivity
   : The RxSight Light Adjustable Lens is the
   only
   intraocular lens adjustable after surgery
2. Clinical Value
   : Delivers personalized vision correction with high patient satisfaction
3. First-Mover Advantage
   : Over 250,000 procedures performed to date
4. Integrated Commercial Team
   : Combined clinical and sales teams to deepen customer relationships [3]

• The better-than-expected Q4 results are expected to boost market confidence
• The J.P. Morgan Healthcare Conference (January 13, 2026) may serve as a catalyst
• The release of the full annual report (February 24, 2026) will provide clearer guidance

• International market expansion (appointment of Executive Vice President of International Operations)
• Continued growth in premium IOL market share
• Steady growth in procedure volume (12% year-over-year)

• Continued growth in cataract procedures (aging population trend)
• Technological iteration (LAL + next-generation products)
• Global market access

Risk Type	Details	Impact Level
Financial Risk	Sustained losses (net profit margin -20.52%)	High
Operational Risk	Transition period following CFO departure	Medium-High
Market Risk	Sharp fluctuations in LDD sales	Medium
Competitive Risk	Entry of industry giants / technological substitution	Medium
Regulatory Risk	Product approval / medical insurance reimbursement	Low

---

Despite the better-than-expected Q4 revenue, the stock price fell following the announcement (1-day decline of -7.63%), which reflects:

• Market concerns over the CFO’s departure outweighed positive sentiment from the results
• Previous gains had already priced in optimistic expectations
• Weak overall market conditions (pullback in the medical device sector)

• Current P/S ratio of 2.31x is below the historical average
• Given sustained losses, the market remains skeptical about profitability prospects
• The oversold condition may present a mid-to-long-term allocation opportunity

Dimension	Assessment	Rating
Q4 Results	Better-than-expected but structural issues remain	Neutral
Stock Performance	Extremely oversold with rebound potential	Bullish-Tilted
Guidance Upgrade Upside	Limited, execution to be monitored	Neutral
Growth Sustainability	Solid mid-term, long-term to be verified	Neutral-Bullish
Risk/Reward Ratio	Limited downside risk with upside potential	Attractive

• Long-term investors with high risk tolerance
• Investors bullish on the innovative intraocular lens technology track
• Investors who can tolerate short-term volatility and seek mid-term rebounds

• The current results are preliminary, and adjustments may be made in the full report
• The CFO transition period may impact investor confidence
• Fluctuations in LDD sales may impact quarterly results
• High stock price volatility (Beta 1.14)

---

The short-term impact of RxSight’s better-than-expected Q4 revenue on its stock price is

—the positive results were offset by negative factors such as the CFO’s departure. Technical indicators show the stock is extremely oversold (RSI 15.37), with potential for a technical rebound.

: The company is expected to slightly upgrade its guidance in the full report released in February 2026, but the possibility of a significant upgrade is low due to constraints from volatile LDD sales and uncertainties during the CFO transition period.

: With its unique technological advantages and growing market share, the company is expected to maintain solid growth, but management stability and execution capabilities need to be closely monitored.

---

[0] Gilin API Data - RxSight Financial Analysis, Market Data, Technical Indicators (2026-01-11)

[1] GlobeNewswire - “RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer” (2026-01-11) https://www.globenewswire.com/en/news-release/2026/01/11/3216471/0/en/RxSight-Inc-Announces-Preliminary-Q4-and-2025-Financial-Results-New-Chief-Financial-Officer.html

[2] Investing.com - “RxSight CFO exit raises concerns over pace of recovery, BTIG says” (2025-12-23) https://www.investing.com/news/stock-market-news/rxsight-cfo-exit-raises-concerns-over-pace-of-recovery-btig-says-4421583

[3] Yahoo Finance - “RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference” (2026-01-02) https://finance.yahoo.com/news/rxsight-inc-present-j-p-210500517.html